BioSpace News Archive

Highly statistically significant improvements in PEC score observed vs. placebo (p<0.0001) at two hours in the SERENITY trials for both doses tested

Kedrion Biopharma, an Italian biopharmaceutical company and world player in the field of plasma-derived therapies, has formed a research partnership with Columbia University Irving Medical Center to develop and test a new IgG therapy for COVID-19 which is being developed by Kedrion and Kamada Ltd, a leading Israeli bio-pharmaceutical company that specializes in plasma derived products.

Company to Host Conference Call on Wednesday, August 5, 2020 at 1:30 p.m. PT / 4:30 p.m. ET.

IMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, announced the appointment of Michael P. Bailey to its Board of Directors.

Orthofix Medical Inc., a global medical device company focused on musculoskeletal healing products, announced it has received the U.S. Food and Drug Administration 510 clearance and European CE Mark approval for the JuniOrtho® Plating System.

Company Considering Conducting In Vitro Testing Combining Brilacidin with Remdesivir™

Acerus Announces Launch of NATESTO ® Specialty Sales Team in the United States Initially 22 in Size, Dedicated Staff to Target Urologists and Endocrinologists TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced the launch of a dedicated sales team to promote the Company’s key product,

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced the appointments of Ms. Priyanka Misra as Vice President of Corporate Development and Dr. Elise Brownell as Vice President of Research & Developmen

Program expands access to odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on Shockwave’s Compensation Committee.